Lexeo Therapeutics, Inc. (LXEO) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $8.00K; Additional Paid in Capital, Common StockUSD $661.57M; Treasury Stock, Common, ValueUSD $17.00K; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-298.00K.
- 2026-03-31: Common Stock, Value, IssuedUSD $7.00K; Additional Paid in Capital, Common StockUSD $631.98M; Treasury Stock, Common, ValueUSD $17.00K; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-142.00K.
- 2025-12-31: Common Stock, Value, IssuedUSD $7.00K; Additional Paid in Capital, Common StockUSD $626.62M; Treasury Stock, Common, ValueUSD $17.00K; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $188.00K.
- 2025-09-30: Common Stock, Value, IssuedUSD $5.00K; Additional Paid in Capital, Common StockUSD $479.97M; Treasury Stock, Common, ValueUSD $17.00K; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $89.00K.
Lexeo Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Treasury Stock, Common, Value USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Treasury Stock, Common, Shares shares | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $8.00K | $661.57M | $17.00K | $-298.00K | $-426.20M | $235.06M | 3.83K | (m) |
| 2026-03-31 | $7.00K | $631.98M | $17.00K | $-142.00K | $-400.33M | $231.50M | 3.83K | (m) |
| 2025-12-31 | $7.00K | $626.62M | $17.00K | $188.00K | $-380.13M | $246.67M | 3.83K | (m) |
| 2025-09-30 | $5.00K | $479.97M | $17.00K | $89.00K | $-359.21M | $120.83M | 3.83K | (m) |
| 2025-06-30 | $5.00K | $477.18M | $17.00K | $-13.00K | $-338.93M | $138.22M | 3.83K | (m) |
| 2025-03-31 | $3.00K | $401.01M | $17.00K | $-54.00K | $-312.83M | $88.11M | 3.83K | (m) |
| 2024-12-31 | $3.00K | $397.13M | $17.00K | $-103.00K | $-280.17M | $116.84M | 3.83K | (m) |
| 2024-09-30 | $3.00K | $393.58M | $13.00K | (m) | $-254.25M | $139.33M | 2.99K | (m) |
| 2024-06-30 | $3.00K | $389.72M | $13.00K | (m) | $-224.76M | $164.95M | 2.99K | (m) |
| 2024-03-31 | $3.00K | $386.47M | (m) | (m) | $-224.80M | $182.95M | (m) | (m) |
| 2023-12-31 | $3.00K | $295.37M | (m) | (m) | $-181.84M | $113.53M | 0.00 | 12 month · $4.42M |
| 2023-09-30 | $0.00 | $4.84M | (m) | (m) | $-167.65M | $-162.81M | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | $-143.62M | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | $-131.18M | (m) | (m) |
| 2022-12-31 | $0.00 | $2.49M | (m) | (m) | $-115.45M | $-112.95M | (m) | (m) |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | $-98.98M | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | $-82.42M | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | $-67.83M | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | $-55.60M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |